Interaction Summary
At a Glance| Parameter | Detail |
|---|---|
| Drug | Warfarin (Coumadin, Jantoven) |
| Substance | Cannabis — CBD (cannabidiol), THC (tetrahydrocannabinol) |
| Severity | ⬛ Major |
| Primary Mechanism | CBD inhibits CYP2C9 → S-warfarin accumulates → elevated INR → increased bleeding risk |
| Evidence Level | Published case series (multiple) + FDA prescribing information for pharmaceutical CBD (Epidiolex) |
| Clinical Effect | Elevated INR; documented cases required warfarin dose reduction |
| Prescriber Disclosure | Required. Changes in cannabis use require INR monitoring adjustment. |
The Mechanism: How CBD Raises Warfarin Levels
Clinical PharmacologyWarfarin Exists as Two Forms — One Is More Potent
Warfarin is a racemic mixture of two mirror-image molecules: S-warfarin and R-warfarin. S-warfarin is approximately 3–5 times more pharmacologically potent than R-warfarin as an anticoagulant. The ratio of these two forms determines the drug's clinical effect. NIH MedlinePlus
S-Warfarin Is Metabolized Almost Exclusively by CYP2C9
S-warfarin is cleared from the body primarily through the liver enzyme CYP2C9. This single-enzyme dependency is what makes warfarin unusually sensitive to CYP2C9 inhibition. When CYP2C9 is inhibited, S-warfarin stays in the bloodstream longer and at higher concentrations than the prescribed dose was designed to produce. FDA Warfarin PI
CBD Is a Documented CYP2C9 Inhibitor
Cannabidiol (CBD) inhibits CYP2C9 at concentrations achievable through common cannabis products. This is documented in the FDA prescribing information for Epidiolex (pharmaceutical-grade CBD) under the drug interactions section, and confirmed in pharmacokinetic research. The result of CBD adding CYP2C9 inhibition to a stable warfarin regimen: S-warfarin accumulates, INR rises. FDA Epidiolex PI, NDA 210365
THC Also Has Anticoagulant Properties
THC has independent effects on platelet function — some evidence suggests THC may inhibit platelet aggregation, which could add to warfarin's anticoagulant effect through a separate mechanism beyond enzyme inhibition. The clinical significance of THC-alone effects on warfarin is less well-characterized than the CBD-CYP2C9 pathway, but both cannabinoids are potentially relevant. Yamreudeewong et al., 2009
What the Published Case Reports Show
Clinical EvidenceCase Series: CBD + Warfarin (Grayson et al., 2018)
Researchers at the University of Alabama at Birmingham published a case series of patients who were on stable warfarin therapy and added CBD as an adjunct treatment for epilepsy. Epilepsy & Behavior, 2018
Across the cases documented, warfarin dose reductions were required to maintain patients within their target INR range after CBD was initiated. The interaction was consistent with CBD-mediated CYP2C9 inhibition — the mechanism predicted by pharmacokinetic data. The authors concluded that patients on warfarin who initiate CBD require more frequent INR monitoring and likely warfarin dose adjustment.
The patients in this case series were using pharmaceutical-grade CBD (Epidiolex) under clinical supervision, which allowed the interaction to be identified and managed with INR monitoring. Cannabis obtained through consumer channels is not monitored this way — making proactive prescriber disclosure even more important.
Case Reports: Smoked Cannabis + Warfarin (Yamreudeewong et al., 2009)
A published case series in the Annals of Pharmacotherapy documented probable interactions between smoked marijuana and warfarin in patients on stable anticoagulation therapy. Ann Pharmacother, 2009
These reports are significant because they involve smoked cannabis — which bypasses first-pass liver metabolism — confirming that systemic cannabinoids reach the liver in concentrations sufficient to affect CYP2C9 activity even when the oral route is bypassed. Authors rated these interactions as probable based on established pharmacokinetic causality criteria.
DOACs: Apixaban, Rivaroxaban, Dabigatran
Beyond WarfarinNewer blood thinners — direct oral anticoagulants (DOACs) — have a different but still relevant interaction profile with cannabis.
Clinical Guidance for Patients on Warfarin
Prescriber ConversationIf you take warfarin and use cannabis — or are considering starting — these are the key points for discussion with the prescriber managing your anticoagulation:
- Disclose cannabis use fully — including product type (CBD oil, full-spectrum edibles, smoked flower), frequency, and approximate dose if known.
- Request more frequent INR monitoring when initiating, increasing, or changing the form of cannabis use.
- Report any unusual bruising, prolonged bleeding, or blood in urine — these may indicate INR elevation.
- Do not adjust warfarin dose yourself based on suspected cannabis interactions. INR monitoring and dose adjustment must be done in coordination with your prescriber.
- Consistency matters — changes in cannabis use (starting, stopping, changing products, changing dose) are the situations that most often produce clinically significant INR shifts. Stable, consistent use in someone whose INR is monitored and optimized may be more manageable than unpredictable changes.
- CBD-dominant products carry the highest pharmacokinetic risk — but smoked cannabis has also been documented to affect warfarin. All forms warrant disclosure.
Frequently Asked Questions
Common QueriesCan I use CBD while taking warfarin? ▼
CBD is not categorically contraindicated with warfarin, but the combination requires active prescriber management, more frequent INR monitoring, and likely warfarin dose adjustment. Published case reports document that CBD-warfarin co-use without monitoring adjustments can produce INR elevation and bleeding risk. Whether co-use is appropriate for an individual patient depends on the clinical context — it is a prescriber decision, not a general safety determination.
If you use CBD and take warfarin, the most important step is disclosing this to whoever manages your anticoagulation. Do not assume the combination is safe because both are legal in your jurisdiction.
Does smoking marijuana increase INR? ▼
Published case reports suggest that smoked cannabis (marijuana) can increase INR in warfarin patients, though the mechanism with smoked cannabis is less direct than with oral CBD. Smoked cannabis bypasses first-pass liver metabolism, but systemic cannabinoids still circulate through the liver where CYP2C9 inhibition can occur. Yamreudeewong et al. (2009) documented probable warfarin interactions with smoked marijuana in published cases.
Whether smoked cannabis produces a smaller INR elevation than oral CBD products is plausible based on pharmacokinetic reasoning, but has not been established in clinical studies comparing routes. All forms of cannabis use should be disclosed to the prescriber managing warfarin therapy.
How quickly would cannabis affect my INR? ▼
The timeline for a cannabis-related INR elevation depends on the form of cannabis, the dose, and individual pharmacokinetics. With oral CBD products, enzyme inhibition begins with first use, but INR changes may not become measurable for several days as warfarin accumulates. For smoked cannabis, the onset of systemic cannabinoid exposure is faster, but the INR consequences follow the same warfarin accumulation timeline.
Clinically, when new cannabis use is initiated or an existing dose is significantly increased, INR should be rechecked within approximately 5–7 days to identify any emerging elevation. This is the clinical practice consistent with initiating any new CYP2C9 inhibitor in a warfarin patient.
Is the cannabis-warfarin interaction worse with edibles than with smoking? ▼
For the CYP2C9-warfarin mechanism specifically, oral cannabis (edibles, tinctures) carries higher pharmacokinetic interaction risk than inhaled cannabis. This is because oral cannabis is processed through the gastrointestinal tract and liver (first-pass metabolism), placing high concentrations of CBD and THC in direct contact with the liver enzymes responsible for drug metabolism before reaching systemic circulation. Inhaled cannabis bypasses this first-pass effect.
However, as documented case reports with smoked cannabis confirm, the distinction is relative — not absolute. Inhaled cannabis still delivers cannabinoids to the liver through systemic circulation, and warfarin interactions have been reported with smoked cannabis as well. All routes of cannabis use are clinically relevant to a warfarin patient.
View credentials → · Verify NPI →
Primary Sources
- Grayson L, Vines B, Nichol K, Szaflarski JP; UAB CBD Program. "An interaction between warfarin and cannabidiol, a case series." Epilepsy & Behavior. 2018 Jun;83:201-203. PMID: 29680592.
https://doi.org/10.1016/j.yebeh.2018.03.031 - Yamreudeewong W, Wong HK, Brausch LM, White K, Deem LA. "Probable interaction between warfarin and marijuana smoking." Annals of Pharmacotherapy. 2009 Jul;43(7):1347-53. PMID: 19584395.
https://doi.org/10.1345/aph.1L578 - FDA. Epidiolex (cannabidiol) Prescribing Information. NDA 210365. Section 7: Drug Interactions — documents CYP2C9 inhibition and warfarin interaction potential.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210365s006lbl.pdf - NIH MedlinePlus. Warfarin. National Library of Medicine. Drug information including CYP2C9 metabolism and interaction warnings.
https://medlineplus.gov/druginfo/meds/a682277.html
Check Your Full Medication List
Warfarin is rarely taken alone. Use InteractSafe to review all your prescriptions and supplements together.
Open the Interaction Checker →Free · No account required · Not medical advice